Abstracts tagged "outcomes"

Abstract Number: 2918 • 2015 ACR/ARHP Annual Meeting
Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?
Zahi Touma¹, Murray Urowitz^2,3, Jorge Medina-Rosas⁴, Jiandong Su¹ and Dafna Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The tempo of Complete Proteinuria Recovery (CPR) in Lupus Nephritis (LN) is slow and while 28% achieve CPR at year 1 this increases to…
Abstract Number: 418 • 2015 ACR/ARHP Annual Meeting
Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity
Kaveh Ardalan¹, Nicole Hershey¹, Jonathan Yabes², Kathryn S. Torok¹ and The CARRA Registry Investigators, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune skin and soft tissue disease that causes morbidity via progressive skin fibrosis and extracutaneous manifestations (ECMs), such…
Abstract Number: 2930 • 2015 ACR/ARHP Annual Meeting
Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Samar Alharbi¹, Jiandong Su², Stacey E. Morrison³, Mohammed Attar⁴, Khawla Al-Ghanim⁵, Murray Urowitz^6,7, Dafna Gladman² and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, University Health Network, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To assess the impact of thrombotic events (TE) on 1) mortality, 2) SLE-related damage accrual; and 3) health-related quality of life (HRQoL) in patients…
Abstract Number: 442 • 2015 ACR/ARHP Annual Meeting
Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
Andrew Holman¹ and Edmund Ng², ¹Inmedix, Normandy Park, WA, ²Statistical Thinking, Seattle, WA
Background/Purpose: As a proposed inflammatory biomarker for autoimmune disease1,2, the autonomic nervous system (ANS) has been assessed as a predictor of anti-TNF treatment outcome3 and…
Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Kichul Ko¹, Alana B. Levine², Russell Griffin³, Olga Dvorkina⁴, Saira Sheikh⁵, Jinoos Yazdany⁶, Richard Furie⁷ and Cynthia Aranow⁸, ¹Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ⁸Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…
Abstract Number: 567 • 2015 ACR/ARHP Annual Meeting
Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature
William Monaco¹, William F.C. Rigby² and Jonathan Jones³, ¹Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Rituximab (RTX) has been associated with late onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1.5 x 109/L at least 4 weeks…
Abstract Number: 2985 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database
Lesley Ann Saketkoo¹, Dörte Huscher², Christopher P. Denton³, Gabriela Riemekasten⁴, Virginia D. Steen⁵, Oliver Distler⁶ and EUSTAR member centres, ¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Clinic of Rheumatology, University of Luebeck, Lübeck, Germany, ⁵Rheumatology, Georgetown University Medical Center, Washington, DC, ⁶Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland
Background/Purpose : SSc related PH carries a high mortality; with SSc-PH related to restrictive lung disease (RLD) having worse prognosis and more rapid time to…
Abstract Number: 852 • 2015 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Early Systemic Sclerosis
Marie Hudson¹, Murray Baron², Mianbo Wang³, Candice Rabusa⁴, Susanna Proudman⁵, Mandana Nikpour⁶, Wendy Stevens⁴ and Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Cohort Study (ASCS), ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁶University of Melbourne Department of Medicine, Melbourne, Australia
Background/Purpose: Health-related quality of life (HRQoL) research is a priority in systemic sclerosis (SSc). Yet, much of the data comes from prevalent cohorts with established…
Abstract Number: 2986 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients on Intensive Care Unit – Reasons for Admission and Determinants of Outcome
Svetlana I. Nihtyanova¹, Francesco Figorilli², Christopher P. Denton³, Banwari Agarwal² and Voon H. Ong¹, ¹Rheumatology, UCL Division of Medicine, London, United Kingdom, ²ITU, Royal Free Hospital, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Little has been published on systemic sclerosis (SSc) patients requiring admission to Intensive Care Unit (ICU) for organ support; published results suggest respiratory failure…
Abstract Number: 921 • 2015 ACR/ARHP Annual Meeting
Poverty Associated with Increase in Damage in SLE over Two-Year Period
Edward H. Yelin¹, Laura Trupin², Jinoos Yazdany² and Stephanie Rush³, ¹University of California, San Francisco, San Francisco, CA, ²Rheumatology, UCSF, SF, CA, ³UCSF, SF, CA
Background/Purpose: Prior research has shown that persons with SLE in poverty have fewer physician visits for SLE and receive lower technical quality of care.…
Abstract Number: 3068 • 2015 ACR/ARHP Annual Meeting
Damage Assessment in Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹⁴ and Peter A. Merkel⁸, ¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of California Los Angeles, Santa Monica, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶McMaster University, Hamilton, ON, Canada, ⁷Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹²Division of Rheumatology, Johns Hopkins, Baltimore, MD, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: This study aimed to describe disease-related damage in Takayasu's arteritis (TAK) and evaluate damage assessment tools using data from a large longitudinal cohort. …
Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
Abstract Number: 3207 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: A Clinical and Radiographic Comparison with Ankylosing Spondylitis
Deepak R. Jadon¹, Raj Sengupta¹, Alison L Nightingale², Mark Lindsay³, Eleanor Korendowych¹, Graham Robinson⁴, Amelia Jobling⁵, Gavin Shaddick⁶, Anne Barton⁷ and Neil J. McHugh⁸, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁴Royal United Hospital, Bath, United Kingdom, ⁵Mathematical Sciences, University of Bath, Bath, United Kingdom, ⁶Department of Mathematics, University of Bath, Bath, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁸Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: Little is known of the characteristics of psoriatic spondyloarthritis (PsSpA). A study was conducted to determine the: (i) prevalence of PsSpA in a psoriatic…
Abstract Number: 1286 • 2015 ACR/ARHP Annual Meeting
Persistent Individual and Neighborhood Poverty Are Independent Risk Factors for Accumulated Lupus Damage
Laura Trupin¹, Stephanie Rush², Jinoos Yazdany³ and Edward H. Yelin⁴, ¹Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ²UCSF, SF, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, UC San Francisco, San Francisco, CA
Title: Persistent Individual and Neighborhood Poverty Are Independent Risk Factors for Accumulated Lupus Damage Background/Purpose: Previous research in systemic lupus erythematosus (SLE) has shown that…
Abstract Number: 1422 • 2015 ACR/ARHP Annual Meeting
Pain after Total Knee Arthroplasty: Poverty Modifies the Effect of Race and Education
Susan M. Goodman¹, Anne R. Bass¹, Michael Parks², Kelly McHugh¹, Meng Zhang³, Joseph Nguyen³, Yuo-Yu Lee³, Mark P. Figgie⁴ and Lisa Mandl⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Orthopedics, Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Orthopaedics, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Pain after Total Knee Arthroplasty: Poverty Modifies the Effect of Race and Education Background/Purpose: Race and education are important predictors of pain after total knee…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].